Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

NCTID	NCT06517888 (View at clinicaltrials.gov)
Description	This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance. (Show More)
Development Status	Active
Indication	Vestibular Schwannoma
Disease Ontology Term	DOID:3204
Compound Name	AAVAnc80-antiVEGF
Sponsor	Akouos, Inc.
Funder Type	Industry
Recruitment Status	Recruiting
Enrollment Count	27
Results Posted	Not Available

Target Gene/Variant	Anti-VEGF
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Intracochlear
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAVAnc80
Editor Type	none
Dose 1	Undisclosed dose 1
Dose 2	Undisclosed dose 2
Dose 3	Undisclosed dose 3
Dose 4
Dose 5

No.of Trial Sites	3
Locations	United States

Has US IND	True
FDA Designations
Recent Updates	Eli Lilly acquired this company in 2022